{"id":"placebo-for-linaclotide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (linaclotide) through comparison. It produces no pharmacological effect and serves only as a comparator to distinguish true drug effects from natural disease progression or placebo response.","oneSentence":"This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:15.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in linaclotide clinical trials (Phase 3)"}]},"trialDetails":[{"nctId":"NCT05760313","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-04-27","conditions":"Functional Constipation","enrollment":19},{"nctId":"NCT05652205","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-12-29","conditions":"Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)","enrollment":123},{"nctId":"NCT06091735","phase":"NA","title":"Clinical Study of Bowel Preparation Before Colonoscopy","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2023-08-01","conditions":"Bowel Preparation","enrollment":444},{"nctId":"NCT04026113","phase":"PHASE3","title":"Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-10-01","conditions":"Functional Constipation, Irritable Bowel Syndrome With Constipation","enrollment":438},{"nctId":"NCT02809105","phase":"PHASE3","title":"A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-24","conditions":"Chronic Constipation","enrollment":186},{"nctId":"NCT05379491","phase":"NA","title":"Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation","status":"COMPLETED","sponsor":"Zhiguo Liu","startDate":"2022-08-01","conditions":"Colonoscopy","enrollment":720},{"nctId":"NCT03119584","phase":"PHASE4","title":"Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation","status":"UNKNOWN","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2015-09-01","conditions":"Chronic Constipation, Diabete Mellitus","enrollment":23},{"nctId":"NCT04110145","phase":"PHASE2","title":"Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-10-14","conditions":"Functional Constipation","enrollment":35},{"nctId":"NCT02559817","phase":"PHASE2","title":"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2015-11-01","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":101},{"nctId":"NCT03573908","phase":"PHASE3","title":"A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2018-06-20","conditions":"Irritable Bowel Syndrome Characterized by Constipation","enrollment":614},{"nctId":"NCT02559206","phase":"PHASE2","title":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2015-10-22","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":759},{"nctId":"NCT02559570","phase":"PHASE2","title":"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-11-03","conditions":"Functional Constipation in Children Ages 6-17 Years","enrollment":173},{"nctId":"NCT02270983","phase":"PHASE2","title":"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2014-10-31","conditions":"Opioid-Induced Constipation","enrollment":254},{"nctId":"NCT02078323","phase":"NA","title":"Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients","status":"COMPLETED","sponsor":"Augusta University","startDate":"2014-02","conditions":"Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":39},{"nctId":"NCT02291679","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2014-10","conditions":"Chronic Idiopathic Constipation","enrollment":1223},{"nctId":"NCT02360384","phase":"NA","title":"Caecal pH as a Biomarker for Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"Wingate Institute of Neurogastroenterology","startDate":"2015-11","conditions":"Irritable Bowel Syndrome","enrollment":48},{"nctId":"NCT01880424","phase":"PHASE3","title":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-07","conditions":"Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":1722},{"nctId":"NCT02781493","phase":"PHASE4","title":"Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-06","conditions":"Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp","enrollment":600},{"nctId":"NCT01642914","phase":"PHASE3","title":"Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-08","conditions":"Chronic Constipation, Constipation","enrollment":487},{"nctId":"NCT00938717","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2009-07","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":805},{"nctId":"NCT00948818","phase":"PHASE3","title":"Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-07","conditions":"Irritable Bowel Syndrome Characterized by Constipation","enrollment":803},{"nctId":"NCT00730015","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2008-08","conditions":"Chronic Constipation","enrollment":643},{"nctId":"NCT00765882","phase":"PHASE3","title":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-09","conditions":"Chronic Constipation","enrollment":633},{"nctId":"NCT01427387","phase":"PHASE1","title":"A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06","conditions":"Healthy, Pharmacokinetics of ASP0456","enrollment":44},{"nctId":"NCT00306748","phase":"PHASE2","title":"Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Constipation","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Linaclotide","genericName":"Placebo for Linaclotide","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action. Used for Control arm in linaclotide clinical trials (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}